"10.1371_journal.pone.0096852","plos one","2014-05-09T00:00:00Z","Shi-Ming Li; Ru Chen; Yuan Li; Zhi-Rong Yang; Qiu-Ju Deng; Zheng Zhong; Moh-Lim Ong; Si-Yan Zhan","Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Department of Epidemiology and Health Statistics, Peking University School of Public Health, Beijing, China; Pfizer China, Beijing, China; Department of Genetics, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Hai Dian District, Beijing, China; Pfizer Global Pharmaceuticals, New York, New York, United States of America","Conceived and designed the experiments: SML RC YL ZZ SYZ. Performed the experiments: SML RC. Analyzed the data: SML RC. Contributed reagents/materials/analysis tools: SML RC YL ZZ QJD ZRY. Wrote the paper: SML RC SYZ MLO.","This study was supported by Pfizer China, Beijing. YL, ZZ and MLO are employed by Pfizer. The Latanoprost discussed in this study is manufactured by Pfizer. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2014","05","Shi-Ming Li","SML",8,TRUE,5,2,2,4,TRUE,TRUE,FALSE,0,NA,FALSE
